Medications Most Commonly Associated With Erectile Dysfunction: Evaluation Of The Food And Drug Administration National Pharmacovigilance Database

    July 2022 in “ Sexual Medicine
    Elie Kaplan-Marans, Arshia Sandozi, Mariela Martinez, Jeffrey E. Lee, Ariel Schulman, Jacob B. Khurgin
    TLDR Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.
    The study analyzed the FDA Adverse Event Reporting System (FAERS) from 2010 to 2020 to identify medications most frequently associated with erectile dysfunction (ED). Excluding treatments for ED, the top 20 medications accounted for 6,142 reports of ED, with 5-α reductase inhibitors (5-ARIs) and neuropsychiatric medications making up 46% and 40% of these reports, respectively. Finasteride and dutasteride had the highest Proportional Reporting Ratios (PRRs) of 110.03 and 9.40. The study highlights the need for physicians to be aware of these associations to better counsel patients and improve their quality of life. However, the data does not establish causality and cannot calculate ED incidence rates.
    Discuss this study in the Community →

    Research cited in this study

    13 / 13 results

    Related Community Posts Join

    6 / 1000+ results

      community Proof that finasteride messes with neurosteroids

      in Research/Science  230 upvotes 4 months ago
      Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community NW5 at 19. How many grafts do I need?

      in Transplants  140 upvotes 1 year ago
      A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.

      community Massive study on finasteride side effects released

      in Finasteride/Dutasteride  83 upvotes 1 year ago
      The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

    Similar Research

    5 / 1000+ results